%0 Journal Article
%A Pickhardt, Marcus
%A Tassoni, Michele
%A Denner, Philip
%A Kurkowsky, Birgit
%A Kitanovic, Ana
%A Möhl, Christoph
%A Fava, Eugenio
%A Mandelkow, Eckhard
%T Screening of a neuronal cell model of tau pathology for therapeutic compounds.
%J Neurobiology of aging
%V 76
%@ 0197-4580
%C Amsterdam [u.a.]
%I Elsevier Science
%M DZNE-2020-06834
%P 24-34
%D 2019
%X We have developed a cell-based phenotypic automated high-content screening approach for N2a cells expressing the pro-aggregant repeat domain of tau protein (tauRDΔK), which allows analysis of a chemogenomic library of 1649 compounds for their effect on the inhibition or stimulation of intracellular tau aggregation. We identified several inhibitors and stimulators of aggregation and achieved a screening reproducibility >85
%K Cell Line
%K Drug Evaluation, Preclinical: methods
%K Enzyme Inhibitors: pharmacology
%K Histone Deacetylase Inhibitors
%K Histone Deacetylases: pharmacology
%K Humans
%K Models, Biological
%K Protein Aggregation, Pathological: genetics
%K Protein Aggregation, Pathological: metabolism
%K Signal Transduction: genetics
%K Signal Transduction: physiology
%K Tauopathies: drug therapy
%K Tauopathies: genetics
%K Tauopathies: metabolism
%K p38 Mitogen-Activated Protein Kinases: antagonists & inhibitors
%K tau Proteins: metabolism
%K Enzyme Inhibitors (NLM Chemicals)
%K Histone Deacetylase Inhibitors (NLM Chemicals)
%K tau Proteins (NLM Chemicals)
%K p38 Mitogen-Activated Protein Kinases (NLM Chemicals)
%K Histone Deacetylases (NLM Chemicals)
%F PUB:(DE-HGF)16
%9 Journal Article
%$ pmid:30640040
%R 10.1016/j.neurobiolaging.2018.11.026
%U https://pub.dzne.de/record/140512